March 20 (Reuters) - U.S. Food and Drug
Administration approved Alnylam's drug to treat a rare
and deadly heart disease on Thursday, allowing the entry of a
new type of medicine in a market dominated by Pfizer's ( PFE )
blockbuster Vyndaqel.